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Abstract 
Dear Editor, The recent paper by Chintoh and colleagues (2008) reporting olanzapine-induced dysfunction 
in glucose metabolism, enhanced visceral fat and reduced locomotor activity in female rats was highly 
interesting as it illustrated olanzapine’s ability to replicate aspects of metabolic dysfunction in the rodent 
model in a similar manner to the human scenario. However, contrary to previous reports in the rat and the 
clinic, the authors reported no change in body weight or food intake following olanzapine treatment, 
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Dear Editor, 
The recent paper by Chintoh and colleagues (2008) reporting olanzapine-induced dysfunction 
in glucose metabolism, enhanced visceral fat and reduced locomotor activity in female rats was 
highly interesting as it illustrated olanzapine’s ability to replicate aspects of metabolic 
dysfunction in the rodent model in a similar manner to the human scenario. However, contrary 
to previous reports in the rat and the clinic, the authors reported no change in body weight or 
food intake following olanzapine treatment, questioning the validity of the rat model. For the 
past decade scientists have worked to establish a rodent model that mimics the side-effect of 
metabolic dysfunction induced by some atypical antipsychotic drugs in the clinic, and some 
important experimental considerations have surfaced as a result. In particular, the issue of 
animal gender identified in previous animal model studies of olanzapine-induced weight gain 
(Minet-Ringuet et al., 2006; Pouzet et al., 2003) shadows the legitimacy of the rodent model in 
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its ability to mimic the human scenario. Indeed, reports indicate that male rats are less sensitive 
to olanzapine-induced weight gain than females. For example, contrary to female rats, male 
Sprague Dawley, Wistar and Mol:Wistar Hannover rats treated with olanzapine at a dosage 
range of 1 – 20mg/kg/day failed to exhibit increased food intake or weight gain (Albaugh et al., 
2006; Pouzet et al., 2003). However, Minet-Ringuet et al. (2006) found that olanzapine 
(1mg/kg) treatment for 6-weeks increased adiposity and circulating leptin levels in male rats, 
indicating that olanzapine’s enhancement of adiposity and leptin can be replicated in the rat 
model for both sexes.  
 
Based on clinical data, we suggest that the rodent model of olanzapine-induced weight gain 
mimics aspects of the human situation as studies have revealed gender-related differences in 
the human response to olanzapine treatment. Evidence shows that females with psychotic 
disorder have a 3.6-fold increased risk of weight gain than males (Hakko et al., 2006) and 
previous studies have identified female gender as a risk factor and predictor for weight gain 
associated with olanzapine and other atypical antipsychotics (Gebhardt et al., 2009). In fact, 
Wu and colleagues (2007) reported that female first-episode schizophrenia patients had a 
higher hip to waist ratio, increased insulin-resistance and higher plasma triglycerides than 
males following treatment with olanzapine and clozapine. Kluge and others (2009) found that 
olanzapine significantly increased the BMI of female patients after 1-week treatment, however 
male patients took longer to reach significance, and females exhibited increased skin-fold 
thickness but not males. Females also showed a 2-4 times higher level of plasma leptin than 
males following olanzapine treatment, and this increase was observed earlier in females than in 
male patients (Kluge et al., 2009). Furthermore, female schizophrenia patients are more 
responsive to olanzapine treatment than male patients, regardless of illness chronicity (Usall et 
al., 2007). Female patients also exhibit higher plasma concentrations of the drug than males 
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(Kelly et al., 1999), possibly due to their generally lower lean body mass and increased adipose 
tissue, allowing greater drug storage and leading to higher plasma levels over time (Yonkers et 
al., 1992). Gonadal steroids such as oestrogen, progesterone and testosterone can influence 
food intake and metabolism. Fitzgerald and colleagues (2003) identified significant positive 
correlations between changes in oestrogen levels and alterations in leptin and NPY levels as 
well as BMI and weight gain in female schizophrenia patients treated with olanzapine or 
risperidone. These results suggested that fluctuating gonadal steroid levels may play a role in 
the weight-gain side-effect of atypical antipsychotic drugs and may explain the higher sensitivity 
of females to antipsychotic-induced weight gain, though the exact mechanism is unknown  
(Fitzgerald et al., 2003). Finally, based on waist circumference measurements, olanzapine-
treated male patients are more responsive to nutritional intervention than females 
(Skouroliakou et al., 2009).  
 
Indeed, human studies have shown that atypical antipsychotic-induced weight gain does not 
occur in all patients, and findings from the large-scale Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) study showed an increase of 7% weight gain from baseline 
in 30% of patients treated with olanzapine (Allison et al., 2009).  
 
Taken together, the rodent model olanzapine-induced weight gain cannot completely replicate 
human weight gain side-effect, particularly in male rats. However, the sensitivity of female 
rodents to this side-effect over males appears to be a common observation in the clinic. Future 
studies on sex differences in the rodent model may improve our understanding of the 
mechanisms underlying gender response to antipsychotic effects. 
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